Donald J. Kellerman, SVP, Clinical Development & Med Affairs at MAP Pharmaceuticals, Inc. (MAPP), sold 1,429 shares at $24.73 ($35K) on 2013-02-01, disclosed to the SEC on 2013-02-04.
Scheduled sale ($35k) by SVP, Clinical Development & Med Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ZSAN | BUY | 2016-08-22 | $21K | — | Filing → |